|
1
|
Scully C and Bagan JV: Recent advances in
oral oncology. Oral Oncol. 43:107–115. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Breeze J, Morrison A, Dawson D, Tipper J,
Rehman K, Grew N and Pigadas N: Health-related quality of life
after treatment for neoplasia of the major salivary glands: A pilot
study. Br J Oral Maxillofac Surg. 54:806–811. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
González-García R, Naval-Gías L,
Román-Romero L, Sastre-Pérez J and Rodríguez-Campo FJ: Local
recurrences and second primary tumors from squamous cell carcinoma
of the oral cavity: A retrospective analytic study of 500 patients.
Head Neck. 31:1168–1180. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lindenblatt Rde C, Martinez GL, Silva LE,
Faria PS, Camisasca DR and Lourenço Sde Q: Oral squamous cell
carcinoma grading systems-analysis of the best survival predictor.
J Oral Pathol Med. 41:34–39. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gupta S, Khan H, Kushwaha VS, Husain N,
Negi M, Ghatak A and Bhatt M: Impact of EGFR and p53 expressions on
survival and quality of life in locally advanced oral squamous cell
carcinoma patients treated with chemoradiation. Cancer Biol Ther.
16:1269–1280. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Argiris A: EGFR inhibition for recurrent
or metastatic HNSCC. Lancet Oncol. 16:488–489. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cho HS and Leahy DJ: Structure of the
extracellular region of HER3 reveals an interdomain tether.
Science. 297:1330–1333. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bonner JA, Harari PM, Giralt J, Azarnia N,
Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al:
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head
and neck. N Engl J Med. 354:567–578. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nakamura H, Koizumi H, Kimura H, Marushima
H, Saji H and Takagi M: Epidermal growth factor receptor mutations
in adenocarcinoma in situ and minimally invasive adenocarcinoma
detected using mutation-specific monoclonal antibodies. Lung
Cancer. 99:143–147. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mabry R, Gilbertson DG, Frank A, Vu T,
Ardourel D, Ostrander C, Stevens B, Julien S, Franke S, Meengs B,
et al: A dual-targeting PDGFRbeta/VEGF-A molecule assembled from
stable antibody fragments demonstrates anti-angiogenic activity in
vitro and in vivo. MAbs. 2:20–34. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Buday L and Downward J: Roles of cortactin
in tumor pathogenesis. Biochim Biophys Acta. 1775:263–273.
2007.PubMed/NCBI
|
|
12
|
Wu H, Reynolds AB, Kanner SB, Vines RR and
Parsons JT: Identification and characterization of a novel
cytoskeleton-associated pp60src substrate. Mol Cell Biol.
11:5113–5124. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Belsches AP, Haskell MD and Parsons SJ:
Role of c-Src tyrosine kinase in EGF-induced mitogenesis. Front
Biosci. 2:d501–d518. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Meiler E, Nieto-Pelegrín E and
Martinez-Quiles N: Cortactin tyrosine phosphorylation promotes its
deacetylation and inhibits cell spreading. PLoS One. 7:e336622012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kruchten AE, Krueger EW, Wang Y and
McNiven MA: Distinct phospho-forms of cortactin differentially
regulate actin polymerization and focal adhesions. Am J Physiol
Cell Physiol. 295:C1113–C1122. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Halon A, Donizy P, Biecek P,
Rudno-Rudzinska J, Kielan W and Matkowski R: HER-2 expression in
immunohistochemistry has no prognostic significance in gastric
cancer patients. ScientificWorldJournal. 2012:9412592012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wolff KD, Follmann M and Nast A: The
diagnosis and treatment of oral cavity cancer. Dtsch Arztebl Int.
109:829–835. 2012.PubMed/NCBI
|
|
18
|
Götz C, Drecoll E, Straub M, Bissinger O,
Wolff KD and Kolk A: Impact of HPV in oral squamous cell carcinoma.
Oncotarget. 7:76704–76712. 2016.PubMed/NCBI
|
|
19
|
Young RJ, Urban D, Angel C, Corry J, Lyons
B, Vallance N, Kleid S, Iseli TA, Solomon B and Rischin D:
Frequency and prognostic significance of p16 (INK4A) protein
overexpression and transcriptionally active human papillomavirus
infection in laryngeal squamous cell carcinoma. Br J Cancer.
112:1098–1104. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kolk A, Jubitz N, Mengele K, Mantwill K,
Bissinger O, Schmitt M, Kremer M and Holm PS: Expression of
Y-box-binding protein YB-1 allows stratification into long- and
short-term survivorsof head and neck cancer patients. Br J Cancer.
105:1864–1873. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fedchenko N and Reifenrath J: Different
approaches for interpretation and reporting of immunohistochemistry
analysis results in the bone tissue - a review. Diagn Pathol.
9:2212014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bondarenko A, Angrisani N,
Meyer-Lindenberg A, Seitz JM, Waizy H and Reifenrath J:
Magnesium-based bone implants: Immunohistochemical analysis of
peri-implant osteogenesis by evaluation of osteopontin and
osteocalcin expression. J Biomed Mater Res A. 102:1449–1457. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Su CM, Chang TY, Hsu HP, Lai HH, Li JN,
Lyu YJ, Kuo KT, Huang MT, Su JL and Chen PS: A novel application of
E1A in combination therapy with EGFR-TKI treatment in breast
cancer. Oncotarget. 7:63924–63936. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xue ZX, Wen WX, Zhuang Y, Hua ZJ and Xia
YN: Comparison of the efficacy of icotinib in patients with
non-small-cell lung cancer according to the type of epidermal
growth factor receptor mutation. Mol Clin Oncol. 5:265–268. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Grandis JR, Zeng Q, Drenning SD and
Tweardy DJ: Normalization of EGFR mRNA levels following restoration
of wild-type p53 in a head and neck squamous cell carcinoma cell
line. Int J Oncol. 13:375–378. 1998.PubMed/NCBI
|
|
26
|
Baschnagel AM, Tonlaar N, Eskandari M,
Kumar T, Williams L, Hanna A, Pruetz BL and Wilson GD: Combined
CD44, c-MET, and EGFR expression in p16-positive and p16-negative
head and neck squamous cell carcinomas. J Oral Pathol Med.
46:208–213. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hrustanovic G, Lee BJ and Bivona TG:
Mechanisms of resistance to EGFR targeted therapies. Cancer Biol
Ther. 14:304–314. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Scott AM, Allison JP and Wolchok JD:
Monoclonal antibodies in cancer therapy. Cancer Immun.
12:142012.PubMed/NCBI
|
|
29
|
Andreadis C, Vahtsevanos K, Sidiras T,
Thomaidis I, Antoniadis K and Mouratidou D: 5-Fluorouracil and
cisplatin in the treatment of advanced oral cancer. Oral Oncol.
39:380–385. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pasini F, Fraccon AP, Modena Y, Bencivenga
M, Giacopuzzi S, La Russa F, Gusella M and de Manzoni G: Targeted
therapies for advanced and metastatic adenocarcinoma of the
gastroesophageal junction: Is there something new? Gastric Cancer.
20:31–42. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Neumair P, Joos L, Warschkow R, Dutly A,
Ess S, Hitz F, Früh M, Brutsche M, Baty F, Krähenbühl S, et al:
Erlotinib has comparable clinical efficacy to chemotherapy in
pretreated patients with advanced non-small cell lung cancer
(NSCLC): A propensity-adjusted, outcomes research-based study. Lung
Cancer. 100:38–44. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Oliveira-Silva RJ, de Carvalho Carolina A,
de Souza Viana L, Carvalho AL and Reis RM: Anti-EGFR therapy:
Strategies in head and neck squamous cell carcinoma. Recent Pat
Anticancer Drug Discov. 11:170–183. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ma L, Zou B and Yan H: Identifying EGFR
mutation-induced drug resistance based on alpha shape model
analysis of the dynamics. Proteome Sci. 14:122016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jin Y, Zhang W, Wang H, Zhang Z, Chu C,
Liu X and Zou Q: EGFR/HER2 inhibitors effectively reduce the
malignant potential of MDR breast cancer evoked by P-gp substrates
in vitro and in vivo. Oncol Rep. 35:771–778. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Steinway SN, Dang H, You H, Rountree CB
and Ding W: The EGFR/ErbB3 pathway acts as a compensatory survival
mechanism upon c-met inhibition in human c-Met+ hepatocellular
carcinoma. PLoS One. 10:e01281592015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sato H, Hatanaka KC, Hatanaka Y,
Hatakeyama H, Hashimoto A, Matsuno Y, Fukuda S and Sabe H: High
level expression of AMAP1 protein correlates with poor prognosis
and survival after surgery of head and neck squamous cell carcinoma
patients. Cell Commun Signal. 12:172014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Aboshanif M, Kawasaki Y, Omori Y, Suzuki
S, Honda K, Motoyama S and Ishikawa K: Prognostic role of
regenerating gene-I in patients with stage-IV head and neck
squamous cell carcinoma. Diagn Pathol. 11:792016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gupta R, Chetty C, Bhoopathi P, Lakka S,
Mohanam S, Rao JS and Dinh DE: Downregulation of uPA/uPAR inhibits
intermittent hypoxia-induced epithelial-mesenchymal transition
(EMT) in DAOY and D283 medulloblastoma cells. Int J Oncol.
38:733–744. 2011.PubMed/NCBI
|
|
39
|
Yamada S, Yanamoto S, Kawasaki G, Mizuno A
and Nemoto TK: Overexpression of cortactin increases invasion
potential in oral squamous cell carcinoma. Pathol Oncol Res.
16:523–531. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liu HS, Lu HH, Lui MT, Yu EH, Shen W, Chen
YP, Chang KW and Tu HF: Detection of copy number amplification of
cyclin D1 (CCND1) and cortactin (CTTN) in oral carcinoma and oral
brushed samples from areca chewers. Oral Oncol. 45:1032–1065. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Pu YS, Huang CY, Kuo YZ, Kang WY, Liu GY,
Huang AM, Yu HJ, Lai MK, Huang SP, Wu WJ, et al: Characterization
of membranous and cytoplasmic EGFR expression in human normal renal
cortex and renal cell carcinoma. J Biomed Sci. 16:822009.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Michikawa C, Uzawa N, Sato H, Ohyama Y,
Okada N and Amagasa T: Epidermal growth factor receptor gene copy
number aberration at the primary tumour is significantly associated
with extracapsular spread in oral cancer. Br J Cancer. 104:850–855.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gonzales CB, De La Chapa JJ, Saikumar P,
Singha PK, Dybdal-Hargreaves NF, Chavez J, Horning AM, Parra J and
Kirma NB: Co-targeting ALK and EGFR parallel signaling in oral
squamous cell carcinoma. Oral Oncol. 59:12–19. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Stewart EL, Tan SZ, Liu G and Tsao MS:
Known and putative mechanisms of resistance to EGFR targeted
therapies in NSCLC patients with EGFR mutations-a review. Transl
Lung Cancer Res. 4:67–81. 2015.PubMed/NCBI
|
|
45
|
Martini V, Gattazzo C, Frezzato F,
Trimarco V, Pizzi M, Chiodin G, Severin F, Scomazzon E, Guzzardo V,
Saraggi D, et al: Cortactin, a Lyn substrate, is a checkpoint
molecule at the intersection of BCR and CXCR4 signalling pathway in
chronic lymphocytic leukaemia cells. Br J Haematol. 178:81–93.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang ZN, Liu D, Yin B, Ju WY, Qiu HZ, Xiao
Y, Chen YJ, Peng XZ and Lu CM: High expression of PTBP1 promote
invasion of colorectal cancer by alternative splicing of cortactin.
Oncotarget. 8:36185–36202. 2017.PubMed/NCBI
|
